Literature DB >> 33795259

Liquid Biopsy: It's the Bloody Truth!

Nathan M Hawkey1, Andrew J Armstrong2.   

Abstract

Liquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration-resistant prostate cancer. Here we discuss the Foundation Medicine plasma cell-free circulating tumor DNA assay, its pros and cons, and potential clinical utility.See related article by Tukachinsky et al., p. 3094. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33795259      PMCID： PMC8172457          DOI： 10.1158/1078-0432.CCR-21-0531

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  6 in total

1.  Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Authors:  Guru Sonpavde; Neeraj Agarwal; Gregory Russell Pond; Rebecca J Nagy; Roberto H Nussenzveig; Andrew W Hahn; Oliver Sartor; Theodore Stewart Gourdin; Lakshminarayanan Nandagopal; Elisa M Ledet; Gurudatta Naik; Andrew J Armstrong; Jue Wang; Mehmet Asim Bilen; Shilpa Gupta; Petros Grivas; Sumanta K Pal; Richard B Lanman; AmirAli Talasaz; Michael B Lilly
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

2.  Tumor fraction in cell-free DNA as a biomarker in prostate cancer.

Authors:  Atish D Choudhury; Lillian Werner; Edoardo Francini; Xiao X Wei; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah C Reed; Gregory Gydush; Denisse Rotem; Christopher Lo; Mary-Ellen Taplin; Lauren C Harshman; Zhenwei Zhang; Edward P O'Connor; Daniel G Stover; Heather A Parsons; Gad Getz; Matthew Meyerson; J Christopher Love; William C Hahn; Viktor A Adalsteinsson
Journal:  JCI Insight       Date:  2018-11-02

3.  Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.

Authors:  Hanna Tukachinsky; Russell W Madison; Jon H Chung; Ole V Gjoerup; Eric A Severson; Lucas Dennis; Bernard J Fendler; Samantha Morley; Lei Zhong; Ryon P Graf; Jeffrey S Ross; Brian M Alexander; Wassim Abida; Simon Chowdhury; Charles J Ryan; Karim Fizazi; Tony Golsorkhi; Simon P Watkins; Andrew Simmons; Andrea Loehr; Jeffrey M Venstrom; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2021-02-08       Impact factor: 13.801

4.  Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Authors:  Alexander W Wyatt; Matti Annala; Rahul Aggarwal; Kevin Beja; Felix Feng; Jack Youngren; Adam Foye; Paul Lloyd; Matti Nykter; Tomasz M Beer; Joshi J Alumkal; George V Thomas; Robert E Reiter; Matthew B Rettig; Christopher P Evans; Allen C Gao; Kim N Chi; Eric J Small; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506

5.  Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.

Authors:  Kendal Jensen; Eric Q Konnick; Michael T Schweizer; Alexandra O Sokolova; Petros Grivas; Heather H Cheng; Nola M Klemfuss; Mallory Beightol; Evan Y Yu; Peter S Nelson; Bruce Montgomery; Colin C Pritchard
Journal:  JAMA Oncol       Date:  2021-01-01       Impact factor: 31.777

6.  Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Andrew J Armstrong; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; William R Berry; Tian Zhang; Michael R Harrison; Changxue Lu; Yan Chen; Giuseppe Galletti; Joseph D Schonhoft; Howard I Scher; Richard Wenstrup; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George; Susan Halabi
Journal:  JCO Precis Oncol       Date:  2020-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.